Rodriguez-Freixinos V, et al. - Authors analyzed 135 patients with germline(g) and/or somatic(s) BRCA1/2 mutation ovarian cancer (BMOC) who received chemotherapy (CT) from 2006 to 2016 at four cancer centers in Spain to examine the impact of CT in heavily pretreated (≥3 CT lines) patients with germline(g) and/or somatic(s) BMOC. They observed the 6-year overall survival (OS) rate of 69.4% and 71% in BRCA1 or BRCA2 mutation carriers. They noted the median overall time to progression (TTP) of 10.2 months (across all treatment lines beyond second line). They also found an improved prognosis with primary platinum-free interval > 12 months, exposure to platinum-based chemotherapy (PCT) and PARP inhibitors (PARPi).